• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

11.26 +0.18 (+1.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 Next >
News headline image
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
April 24, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 21, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
April 21, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
April 18, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 14, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
April 10, 2026
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
April 07, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.
April 01, 2026
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADMA Biologics, Inc. – ADMA
March 31, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
March 31, 2026
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
March 27, 2026
From Kirby McInerney LLP
Via Business Wire
News headline image
ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm
March 27, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
March 27, 2026
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA BREAKING INVESTIGATION: BFA Law Launches Investigation into ADMA Biologics after Short Seller Report -- Investors Notified to Contact BFA Law
March 26, 2026
From Bleichmar Fonti & Auld LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
March 26, 2026
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
March 26, 2026
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
March 25, 2026
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ADMA Biologics Addresses Misleading Short-Seller Report
March 25, 2026
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
March 02, 2026
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
February 18, 2026
Conference Call Scheduled for February 25, 2026, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
January 12, 2026
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
January 05, 2026
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
November 05, 2025
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025
October 29, 2025
Conference Call Scheduled for November 5, 2025, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
August 06, 2025
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
July 30, 2025
Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
May 07, 2025
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
April 30, 2025
Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
April 29, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap